ZLAB•businesswire•
Zai Lab Announces Updates to China’s National Reimbursement Drug List
Summary
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the following medicines and indications have been renewed in the 2025 National Reimbursement Drug List (NRDL) released by China’s National Healthcare Security Administration (NHSA): VYVGART® (efgartigimod alfa injection) is renewed for the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive; NUZYRA® (omadacycl
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on December 7, 2025 by businesswire